Moclobemide and cognitive behavioral therapy in the treatment of social phobia. A six-month controlled study and 24 months follow up

Neuroendocrinology Letters

Volumn 27, Issue 4, 2006, Pages 473-481

  Praško, Ján ^a   Dockery, Colleen ^a   Horáček, Jiří ^a   Houbová, Petra ^a   Kosová, Jiřina ^a   Klaschka, Jan ^a   Pašková, Beata ^a   Prašková, Hana ^b   Seifertová, Dagmar ^a   Záleský, Richard ^a   Höschl, Cyril ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

Author keywords

24 months follow up; 6 months efficacy; Cognitive behavioural therapy; Controlled study; Moclobemide; Placebo; Social phobia

Indexed keywords

MOCLOBEMIDE; PLACEBO;

ADULT; ANXIETY; ARTICLE; AVOIDANCE BEHAVIOR; BECK ANXIETY INVENTORY; BEHAVIOR THERAPY; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; COGNITIVE THERAPY; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; EXCITEMENT; FEMALE; FOLLOW UP; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; RELAPSE; SIDE EFFECT; SOCIAL PHOBIA;

EID: 33845407253     PISSN: 0172780X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Allgulander C: Paroxetine in social anxiety disorder: a randomized placebo-controlled study. Acta Psychiatr Scand 1999; 100:193-198.
2. American Psychiatric Association. (1994): Diagnostic criteria from DSM-IV, Washington, DC: Author.
3. Barlow DH, Lehman CL: Advances in the psychosocial treatment of anxiety disorders. Arch Gen Psychiatry 1996; 53:727-735.
4. Beck AT a Steer RA. Manual for the Beck Anxiety Inventory. Psychological Corporation. San Antonio TX 1993.
5. Blomhoff S, Tangen Haug T, Hellstrom K, Holme I, Humble M, Madsbu HP, Wold JE: Randomised controlled general practice trial of sertraline, exposure therapy and combined treatment in generalised social phobia. Br J Psychiatry 2001; 179:23-30.
6. Clark DB, Agras WS: The assessment and treatment of performance anxiety in musicians. Am J Psychiatry 1991; 148:598-605.
7. Davidson JRT, Hughes DC, George LK, Blazer DG: The boundary of social phobia. Arch Gen Psychiatry 1994; 51:975-983.
8. DiNardio PA, Moras K, Barlow DH, Rapee RM, and Brown TA: Reliability of DSM-R-R anxiety disorder categories: using the Anxiety Disorders Interview Schedule-Revised. Arch Gen Psychiatry 1993: 50:251-256.
9. Eaton WW, Dryman A, Weissman MM. Panic and phobia. In: LN Robins and DA regier, Eds. Psychiatric Disorders in America: The Epiemiologic Catchment Area Study. New York, NY: The Free Press; 155-179, 1991.
10. Erwing BA, Heimberg RG, Juster H et al: Comorbid anxiety and mood disorders among persons with social anxiety disorder. Behav Res Ther 2002; 40:19-35.
11. Gelernter CS, Uhde TW, Cimbolic R Arnkoff DB, Vittone BJ, Tancer ME, Bartko JJ. Cognitive-behavioral and pharmacological treatments of social phobia. Arch Gen Psychiat 1991; 48:938-945.
12. Guy W (ed.): ECDEU Assessment manual for psychopharmacology. Rockville, U.S. DHEW 1976
13. Haug TT, Hellstrom K, Blomhoff S et al: The treatment of social phobia in general practice. Is exposure therapy feasible? Fam Pract 2000; 17:114-118.
14. Heimberg RG, Salzman D, Holt CS et al: Cognitive-behavioural group treatment for social phobia: Effectiveness at five-year follows up. Cognitive Therapy and Research 1993: 17.
15. Heimberg RG, Liebowitz MR, Hope DA, Schneier FR, Holt CS, Welkowitz LA, Juster HR, Campeas R, Bruch MA, Cloitre M, Fallon B, Klein DF. Cognitive behavioral group therapy vs phenelzine therapy for social phobia: 12-week outcome. Arch Gen Psychiatry 1998; S5:1 133-41.
16. The International Multicenter Clinical Trial Group on Moclobemide in Social Phobia. Moclobemide in social phobia. A double-blind, placebo-controlled clinical study. Eur Arch Psychiatry Clin Neurosci 1997; 247:71-80.
17. Katschnig H, Stein MB, Buller R, on behalf of the International Multicenter Clinical Trial Group on Moclobernicle in social phobia: a double-blind, placebo-controlled clinical study. Eur Arch Psychiatry Clin Neurosci 1997; 247:71-80.
18. Katzelnick DJ, Kobak KA, Griest JH et al: Sertraline for social phobia: a double-blind, placebo-controlled crossover study. Am J Psychiatry 1995; 152:1368-1371.
19. Kessler RC, McGonagle K, Zhao S, Nelson C, Hughes M, Eschleeman S, Wittchen HU and Kendler KS: Lifetime and 12-months prevalence of DSM-111-R psychiatric disorders in the United States. Arch Gen Psychiatry 1994:51: 8-19
20. Liebowitz MR: Social phobia. Modern Problems in Pharmacopsychiatry 1987; 22:141-173.
21. Liebowitz MR, Heimberg RG, Schneier RF et al: Cognitive-behavioral group therapy versus phenelzine in social phobia: long-term outcome. Depress Anxiety 1999; 10:89-98.
22. Noyes R Jr, Moroz G, Davidson JR, Liebowitz MR, Davidson A, Siegel J, Bell J, Cain JW, Curlik SM, Kent TA, Lydiard RB, Mallinger AG, Pollack MH, Rapaport M, Rasmussen SA, Hedges D, Schweizer E, Uhlenhuth EH. Moclobemide in social phobia: a controlled doseresponse trial. J Clin Psychopharmacol 1997; 17:247-54.
23. Nutt D, Montgomery SA: Moclobemide in the treatment of social phobia. Int. Clin. Psychopharmacol. 1996; 11 (suppl 3):77-82.
24. Oosterbaan DB, van Balkon AJLM, Spinoven P et al. Cognitive therapy versus moclobemide in social phobia: A controlled study. Clin Psychol Psychother 2001; 8:263-273.
25. Regier DA, Farmer ME, Rae DS et al.: Comorbidity of mental disorders with alcohol and other drug abuse: results from the Epidemiologic Catchment Area (ECA) study. JAMA 1990; 264:2511-2518.
26. Sanderson WC, Di Nardo PA, Rapee RM et al: Syndrome comorbidity in patients diagnosed with a DSM-III-R anxiety disorder. J Abnormal Psychol 1990; 99:308-312.
27. Schneier FR, Goetz D, Campeas R, Fallon B, Marshall R, Liebowitz MR: Placebo-controlled trial of moclobemide in social phobia. Br J Psychiatry 1998; 172:70-77.
28. Solyom L, Ledwige B, Solyom C: Delineating social phobia. Br J Psychiatry 1986; 149:464-470.
29. Stein MB, Chartier MJ, Hazen AL et al: Paroxetine in the treatment of generalized social phobia: open-label treatment and double-blind placebo-controlled discontinuation. J Clin Psychopharmacol 1996; 16:218-222.
30. Stein MB, Fyer AJ, Davidson JRT et al: Fluvoxamine treatment of social phobia (social anxiety disorder): a double-blind, placebo-controlled study. Am J Psychiatry 1999; 156:756-760.
31. van Ameringen MA, Lane RM, Walker JR et al: Sertraline treatment of generalized social phobia: a 20-week, double-blind, placebo-controlled study. Am J Psychiatry 2001; 158:275-281.
32. Van der Linden GHH, Stein DJ, van Balkon AJLM: The efficacy of the selective serotonin reuptake inhibitors for social anxiety disorder (social phobia): A meta-analysis of randomized controlled trials. Int Clin Psychopharmacol 2000; 15(Suppl 2) S15-S23.
33. van Vliet IM, den Boer JA, Westenberg HG: Psychopharmacological treatment of social phobia: a double-blind pfacebo controlled study with fluvoxamine. Psychopharmacology 1994; 115:128-134.
34. Versiani M, Nardi AE, Mundim FD, Alves AB, Liebowitz MR, Amrein R. Pharmacotherapy of social phobia. A controlled study with moclobemide and phenelzine. Br J Psychiatry 1992; 161:353-60).